Loading…
← CockpitCompetitor Analysis › KURA Kura Oncology, Inc.Open in the cockpit ↗

Kura Oncology, Inc.KURACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 13
Mkt cap
$674M
US dollars, full cap
Free float
97%
of shares outstanding
$/day
$20.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 7.8%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$7.34
1D-2.0%
1W-5.0%
1M-26.4%
3M-37.3%
6M-29.0%
YTD-29.4%
1Y-32.4%
ATR %9.4%
Beta1.34
52w lowhigh47.2% off high

What Kura Oncology does

Employees: 260

Kura Oncology at a glance

Size Kura Oncology (KURA) is a United States Health Care company (Biotechnology) with a market value of $674M, the 2486th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.34 on 18 Nov 2026.

Performance Over six months the shares fell 29.0%, against -13.8% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue fell 23.8% over the last twelve months (peer median +18.4%); the operating margin is -394.3% (peer median -37.8%).

Valuation It trades at 2.6× enterprise value to sales against a peer median of 8.8× (3rd cheapest of 15).

Short interest Short interest is 14.2% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 87KURA 66
Six months, rebased to 100: Kura Oncology against the median of its 20 peers (local-currency closes).

Kura Oncology financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$79.3M$67.5M$53.9M$0$0
Revenue growth—+25%———
Gross profit$77.3M$66.4M$53.0M-$849,000-$759,000
EBITDA-$311M-$303M-$192M-$165M-$139M
Net income-$293M-$279M-$174M-$153M-$136M
Free cash flow-$89.1M-$70.7M$134M-$125M-$111M
Capital expenditure$3.55M$6.64M$472,000$168,000$626,000
Total debt$25.8M$20.5M$16.6M$17.2M$14.0M

Quarterly statements and history in the cockpit →

Kura Oncology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%77299966301520688221PRMEATTOGERN002880JANXAURASRZNKURA6-month return →1-month return →
Up and to the right = strong over both horizons. Kura Oncology is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%0×50×100×9966301520PRME688197GERNAPMDSRZNKURARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Kura Oncology is the large dot.

Kura Oncology competitors and peer comparison

How Kura Oncology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Kura Oncology against its 20 peers (data as of 18 Nov 2026)
MeasureKURAPeer medianRank in peer set
1-month return-26.4%-7.0%2nd lowest of 21
6-month return-29.0%-13.8%4th lowest of 19
Distance from 52-week high-47.2%-44.5%9th lowest of 21
Revenue growth (TTM)-23.8%+18.4%2nd lowest of 15
Operating margin-394.3%-37.8%5th lowest of 16
EV / Sales2.6×8.8×3rd cheapest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a

Questions

Which companies are Kura Oncology's closest peers?
The cockpit's peer set: Steminent Biotherapeutics (7729.TWO), Alphamab Oncology (9966.HK), Anhui Wanbang Pharmaceutical Technology (301520.SZ), Frontier Biotechnologies (688221.SS), Prime Medicine (PRME), Shouyao Holdings Beijing (688197.SS), Solid Biosciences (SLDB), Attovia Therapeutics (ATTO).
Is Kura Oncology expensive compared with its peers?
On ev / sales it trades at 2.6× against a peer median of 8.8×, 3rd cheapest of 15 in its peer set.
How has Kura Oncology stock performed?
Over six months to 18 Nov 2026 the shares returned -29.0% against -13.8% for the median peer; over one year -32.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.